The company insists that the vaccine is still highly effective even after other diseases are considered in the controversial US study.
new York- AstraZeneca insists today that its Covid-19 vaccine is very effective even after other diseases are considered in its controversial US study.
The company said in a press release that it recalculated the data from the study and concluded that the vaccine is 76% effective in preventing symptomatic Covid-19, instead of the 79% it said a few days ago.
Just a day ago, an independent team overseeing the research accused AstraZeneca of choosing data at its convenience to promote the protection provided by its vaccine. The team stated in a stern letter to the company and the US health authorities that the company has ruled out some Covid-19 cases that occurred during the study, a move that may undermine people’s confidence in science.
During ongoing research, data disputes are usually kept confidential, but in an unusual way, the National Institutes of Health publicly urged AstraZeneca to correct this discrepancy.
The company relies on the results of 32,000 trials conducted mainly in the United States to help restore confidence in the vaccine. Although the vaccine is widely used in the United Kingdom, the European Union and other countries, it has suffered some setbacks in the distribution process. Previous research has provided inconsistent data on its effectiveness, and last week, some countries suspended its application after detecting certain people who applied its clot.
The question now is whether the company’s latest calculation ends this controversy.
The US government’s chief infectious disease expert, Dr. Anthony Fauci, told reporters earlier Wednesday that he hopes that once federal regulators conduct a public assessment of all data, any doubts can be eliminated. He predicted, “It will prove to be a good vaccine.”